decortin 20 mg tablete
merck d.o.o., oreškovićeva ulica 6h/1, zagreb, hrvatska - prednizon - tableta - 20 mg - urbroj: jedna tableta sadrži 20 mg prednizona
decortin 5 mg tablete
merck d.o.o., oreškovićeva ulica 6h/1, zagreb, hrvatska - prednizon - tableta - 5 mg - urbroj: jedna tableta sadrži 5 mg prednizona
momecutan 1 mg/g krema
mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - mometazonfuroat - krema - 1 mg/g - urbroj: 1 g kreme sadrži 1 mg mometazonfuroata
momecutan 1 mg/g mast
mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - mometazonfuroat - mast - 1 mg/g - urbroj: 1 g masti sadrži 1 mg mometazonfuroata
momecutan 1 mg/g otopina za kožu
mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - mometazonfuroat - otopina za kožu - 1 mg/g - urbroj: 1 g otopine za kožu (ekvivalent 1,07 ml) sadrži 1 mg mometazonfuroata
sunitinib pliva 12,5 mg/1 kapsula kapsula, tvrda
pliva d.o.o.sarajevo - sunitinib - kapsula, tvrda - 12,5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 12,5 mg sunitiniba
sunitinib pliva 25 mg/1 kapsula kapsula, tvrda
pliva d.o.o.sarajevo - sunitinib - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg sunitiniba
sunitinib pliva 50 mg/1 kapsula kapsula, tvrda
pliva d.o.o.sarajevo - sunitinib - kapsula, tvrda - 50 mg/1 kapsula - 1 kapsula, tvrda sadrži: 50 mg sunitiniba
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
protopic
leo pharma a/s - takrolimus - dermatitis, atopic - ostali dermatološki pripravci - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. javlja četiri ili više puta godišnje), koji su imali početni odgovor za najviše šest tjedana terapije, dva puta dnevno masti tacrolimus (mjesta očistili, gotovo izbrisani ili slabo utječe).